The global genome editing market size was valued at USD 3.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 22.9% from 2021 to 2028. Increasing implementation of CRISPR genome editing technology coupled with rising synthetic gene demand in diverse biotechnology domains has primarily driven the market growth over the past few years.
Furthermore, the development of CRISPR -based novel diagnostic tools to mitigate the adverse impact of the COVID-19 pandemic is driving the market. For instance, in March 2021, a team of researchers from the Nanyang Technological University developed a diagnostic test - VaNGuard (Variant Nucleotide Guard) based on CRISPR technology. This test can detect mutated SARS-CoV-2 strains, thereby increasing the adoption of CRISPR genome editing technology in the diagnostics arena.
Apart from this, continuous technological advancements in gene-editing tools are a major contributing factor for revenue generation in this market. For instance, in April 2021, researchers from Wyss Institute for Biologically Inspired Engineering at Harvard developed Retron Library Recombineering (RLR) - a new gene-editing tool that enabled the performance of millions of genetic experiments simultaneously, thereby providing better editing rates.
Moreover, the market is witnessing intensified competition among the market players owing to the expanding applications of genome editing tools. There has been an increased focus on the highly adaptable CRISPR technology. For instance, in April 2021, Vertex Pharmaceuticals paid USD 900 million to CRISPR Therapeutics to develop, manufacture and commercialize CRISPR-Cas9 gene-edited therapy for beta-thalassemia and sickle-cell disease. Such initiatives are anticipated to propel market growth.
The expanding gene therapy marketspace has shown significant interest in gene manipulation technologies, thus augmenting the revenue growth. In April 2021, a genome editing consortium announced its plan to develop a new genome editing 'toolkit'. This is aimed to boost gene therapy development. The amount of USD 190 million was granted to the Somatic Cell Genome Editing Consortium for the development of genome editing methods and approaches.
The CRISPR/Cas9 segment dominated the market and accounted for the largest revenue share of 40.2% in 2020. This technique has revolutionized the genome manipulation space with its technical advantages. The advantages include targeted gene disruption, recovery in a guide RNA-specific manner, and regulation. These advantages have accelerated the adoption of CRISPR/Cas9 technology across wider applications.
The clinical applications of CRISPR have been widely accepted. This is evident by the increasing number of ongoing clinical trials using gene-editing techniques for the treatment of a wide range of diseases such as cancer, AIDS, and genetic diseases. Apart from human health, this technology is witnessing increasing usage in agriculture and animal breeding applications.
The limitations of CRISPR technology have increased in applications of the TALEN technique in some hard-to-edit genomic regions. According to a study published in January 2021, TALEN is found to be a more suitable tool for compact DNA studies. Such studies would increase the adoption of the TALEN technique in research settings in the coming years.
The ex-vivo delivery method segment dominated the market and accounted for the largest revenue share of 57.2% in 2020. This can be attributed to the advantages offered by this mode type such as ease of control in DNA modification. The growing clinical trial pipeline that deploys genome editing tools has spurred the ex-vivo delivery segment growth with the increased usage of this delivery method.
On the other hand, the in-vivo gene delivery method accounted for lower revenue generation because of challenges that occurred during the process such as off-target effects. However, focused efforts are being taken to overcome the challenges with growing clinical trials focused on easy target tissues using in-vivo delivery.
The developments in gene editing systems have revolutionized the genetic engineering space, with cell line engineering at the forefront, accounting for the largest revenue share of 58.8% in 2020. This can be attributed to the rapidly growing field of gene and stem cell therapy. The usage of CRISPR gene editing in human-induced pluripotent stem cells (hiPSCs) related programs has important implications in stem cell research for the treatment of various diseases. The clinical application segment dominated the market and accounted for the significant revenue share in 2020.
Furthermore, the CRISPR technology is widely being applied to enhance the productivity of CHO cell lines. These cell lines are prominently used in the production of large molecule therapeutics. Thus, with the application of the CRISPR tool, the biopharmaceutical marketspace is witnessing advancements consequently driving the market for genome editing.
Besides, genetic engineering, genome editing technologies have high potential growth in clinical applications such as diagnostics and therapy development. For instance, an ongoing clinical trial sponsored by Cellectis S.A. is aimed to evaluate the efficacy and safety of UCART123 in patients with R/R Acute Myeloid Leukemia. This therapy is based on TALEN gene-editing technology.
The biotechnology and pharmaceutical companies segment dominated the market and accounted for the largest revenue share of 48.4% in 2020. The presence of a growing number of research activities for novel therapeutic development is the major factor contributing to the segment revenue generation. Moreover, global pharmaceutical companies are collaborating with emerging companies to develop novel technologies.
For instance, in April 2021, CANbridge Pharmaceuticals, Inc. and LogicBio Therapeutics, Inc signed a strategic collaboration and licensing agreement to address rare and serious diseases. Through this agreement, CANbridge Pharmaceuticals, Inc. gained rights to the latter company’s gene-editing platforms. Similarly, in October 2020, Scribe Therapeutics collaborated with Biogen for the development of CRISPR-based genetic medicines for neurological diseases such as Amyotrophic Lateral Sclerosis.
On the other hand, government research and academic institutes are anticipated to witness healthy growth in the near future owing to the increasing uptake of gene-editing technologies in university-level projects. Active engagement of research institutes further supplements the segment growth. For instance, research institutes such as Baylor College of Medicine, Rice University, and Whitehead Institute are actively involved in efforts to advance genome editing.
The contract-based genome editing segment dominated the market and accounted for the largest revenue share of 51.9% in 2020. The high cost of associated infrastructure coupled with increasing collaborations between market entities has resulted in a significant market share of contract services in the global market. For instance, in September 2020, ERS Genomics and Applied StemCell, Inc. signed an agreement for the commercialization of genome editing services.
Similarly, in November 2020, Eli Lilly and the company collaborated with Precision BioSciences, Inc. to use the latter company’s proprietary ARCUS genome editing platform to develop potential in-vivo therapeutics for genetic disorders. Such collaborations have intensified the market competition leading to organic revenue growth.
Well-established companies such as Merck KGaA and Thermo Fisher Scientific are involved in providing custom vectors for cell line editing and engineering. Such services are anticipated to witness growth in the coming years, thereby fueling revenue growth. The rapidly growing demand from gene therapy market players would also propel the revenue generation for contract manufacturers.
North America dominated the genome editing market and accounted for the largest revenue share of 38.4% in 2020. The presence of strong research, as well as a commercial base for advanced therapy development coupled with a high number of clinical trials being conducted for gene and stem cell therapies in the region, has majorly contributed to the dominance of the market in the region.
Furthermore, the increasing number of patents awarded to U.S.-based key players has also accelerated the uptake of these tools in the country leading to significant market growth. For instance, Merck KGaA recently announced that two patents of the company have been approved in the U.S. for CRISPR gene-editing technologies.
On the other hand, in Asia Pacific, the market is anticipated to witness the fastest growth rate throughout the forecast period. In November 2020, China announced its ten most significant advances in the agriculture sector, out of which one was gene-editing technology, thus representing the high market penetration of this space in the country.
Most of the players are undertaking licensing agreements with technology developers to enhance their market presence. For instance, in February 2021, Caribou Biosciences, Inc. and AbbVie signed a license agreement for the research and development of CAR-T therapy. Abbvie gained rights to use Caribou's CRISPR genome editing technology under this agreement.
Similarly, in December 2020, Takara Bio licensed CRISPR genome editing technology from Merck KGaA (Millipore Sigma). This agreement enhanced Takara’s stem cell service capabilities including the development of vectors. Also, in April 2021, Inscripta installed its Onyx CRISPR-based genome editing platform at the University of Liverpool. Such initiatives are expected to positively impact market growth. Some of the prominent players in the genome editing market include:
Merck KGaA
Cibus, Recombinetics, Inc.
Sangamo
Editas Medicine
Precision Biosciences
CRISPR Therapeutics
Intellia Therapeutics, Inc.
Caribou Biosciences, Inc.
Cellectis S.A.
AstraZeneca
Takara Bio USA
Horizon Discovery Group plc
Integrated DNA Technologies, Inc.
Egenesis Inc.
GenScript
New England Biolabs
OriGene Technologies, Inc.
Lonza
Thermo Fisher Scientific, Inc.
Report Attribute |
Details |
Market size value in 2021 |
USD 5.1 billion |
Revenue forecast in 2028 |
USD 19.4 billion |
Growth rate |
CAGR of 22.9% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2017 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million and CAGR from 2017 to 2028 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segment covered |
Technology, delivery method, application, mode, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; France; Italy; Spain; U.K.; China; Japan; South Korea; India; Brazil; Mexico; South Africa; Saudi Arabia |
Companies profiled |
Merck KGaA; Cibus; Recombinetics, Inc.; Sangamo; Editas Medicine; Precision Biosciences; CRISPR Therapeutics; Intellia Therapeutics, Inc.; Caribou Biosciences, Inc.; Cellectis; AstraZeneca; Takara Bio USA; Horizon Discovery Group plc; Integrated DNA Technologies, Inc.; Egenesis Inc.; GenScript; New England Biolabs; OriGene Technologies, Inc.; Lonza; Thermo Fisher Scientific, Inc. |
Customization scope |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global genome editing market report on the basis of technology, delivery method, application, mode, end-use, and region:
Technology Outlook (Revenue, USD Million, 2017 - 2028)
Meganucleases
(CRISPR)/Cas9
TALENs/MegaTALs
ZFN
Others
Delivery Method Outlook (Revenue, USD Million, 2017 - 2028)
Ex-vivo
In-vivo
Mode Outlook (Revenue, USD Million, 2017 - 2028)
Contract
In-house
End-use Outlook (Revenue, USD Million, 2017 - 2028)
Biotechnology and pharmaceutical companies
Academic and government research institutes
Contract research organizations
Application Outlook (Revenue, USD Million, 2017 - 2028)
Genetic Engineering
Cell line engineering
Animal genetic engineering
Plant genetic engineering
Others
Clinical Applications
Diagnostics
Therapy Development
Regional Outlook (Revenue, USD Million, 2017 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
Japan
China
India
South Korea
Latin America
Brazil
Mexico
Middle East and Africa (MEA)
South Africa
Saudi Arabia
b. The global genome editing market size was estimated at USD 3.7 billion in 2020 and is expected to reach USD 5.1 billion in 2021.
b. The global genome editing market is expected to grow at a compound annual growth rate of 22.9% from 2021 to 2028 to reach USD 19.4 billion by 2028.
b. North America dominated the genome editing market with a share of 38.4% in 2020. The presence of strong research, as well as a commercial base for advanced therapy development coupled with a high number of clinical trials being conducted for gene and stem cell therapies in the region, has majorly contributed to the dominance of the region in the global market.
b. Some key players operating in the genome editing market include Caribou Biosciences, Inc., Sangamo, Editas Medicine, Recombinetics, Inc, Thermo Fisher Scientific, Inc., CRISPR THERAPEUTICS, Intellia Therapeutics, Inc., and Sigma Aldrich Corporation.
b. Key factors that are driving the genome editing market growth include success in pre-clinical models drives demands for genome editing therapeutics, rising competition amongst market participants for business development, easy editing solutions for the development of therapeutics for a broad range of diseases, increasing demand for synthetic genes and genetically modified organisms, technological advancements in gene-editing technologies, and rising adoption in agricultural biotechnology.
b. The CRISPR/Cas9 segment dominated the market for genome editing and accounted for the largest revenue share of 40.2% in 2020.
b. The ex-vivo delivery method segment dominated the genome editing market and held the largest revenue share of 57.2% in 2020.
b. The developments in gene editing systems have revolutionized the genetic engineering space, with the cell line engineering application segment accounting for the largest revenue share of 58.8% in 2020.
b. The biotechnology and pharmaceutical companies segment dominated the genome editing market and accounted for the largest revenue share of 48.4% in 2020.
b. The contract-based genome editing mode segment dominated the market, accounting for the largest revenue share of 51.9% in 2020.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for COVID-19. The report will account for COVID-19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.